Search research articles
Contact Us
Filters
Showing results (21-30 of 46) with videos related to
Page
of 5
Sort By:
Molecular Cancer Therapeutics
|
June 24, 2004
Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation
Jie Liu, Chengxiu Li, Wei Qu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 13, 2016
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia
Challice L Bonifant, Arpad Szoor, David Torres, et al.
Transplantation and Cellular Therapy
|
December 7, 2021
Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel
Jonas W Ravich, Sujuan Huang, Yinmei Zhou, et al.
Blood Advances
|
September 26, 2024
EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy
Dua'a Zandaki, Subodh Selukar, Yu Bi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 13, 2022
Targeting glycans for CAR therapy: The advent of sweet CARs
Zoe Raglow, Mary Kathryn McKenna, Challice L Bonifant, et al.
Blood Advances
|
June 10, 2026
PT/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia
Margarita Dionysiou, Yiouli P Ktena, Challice L Bonifant, et al.
Journal of Medicinal Chemistry
|
July 11, 2006
Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo
Paul J Shami, Joseph E Saavedra, Challice L Bonifant, et al.
Haematologica
|
September 11, 2025
Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells
Natalie J Holl, Adam Fearnow, Ilias Christodoulou, et al.
Scientific Reports
|
June 4, 2016
T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies
Mireya Paulina Velasquez, David Torres, Kota Iwahori, et al.
Molecular Therapy. Methods & Clinical Development
|
August 11, 2020
The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing
Janice M Riberdy, Sheng Zhou, Fei Zheng, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 46) with videos related to
Sort By:
Page
of 5
Molecular Cancer Therapeutics
|
June 24, 2004
Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation
Jie Liu, Chengxiu Li, Wei Qu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 13, 2016
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia
Challice L Bonifant, Arpad Szoor, David Torres, et al.
Transplantation and Cellular Therapy
|
December 7, 2021
Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel
Jonas W Ravich, Sujuan Huang, Yinmei Zhou, et al.
Blood Advances
|
September 26, 2024
EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy
Dua'a Zandaki, Subodh Selukar, Yu Bi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 13, 2022
Targeting glycans for CAR therapy: The advent of sweet CARs
Zoe Raglow, Mary Kathryn McKenna, Challice L Bonifant, et al.
Blood Advances
|
June 10, 2026
PT/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia
Margarita Dionysiou, Yiouli P Ktena, Challice L Bonifant, et al.
Journal of Medicinal Chemistry
|
July 11, 2006
Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo
Paul J Shami, Joseph E Saavedra, Challice L Bonifant, et al.
Haematologica
|
September 11, 2025
Early cytokine and chemokine signals shape the anti-AML activity of bispecific engager-secreting T cells
Natalie J Holl, Adam Fearnow, Ilias Christodoulou, et al.
Scientific Reports
|
June 4, 2016
T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies
Mireya Paulina Velasquez, David Torres, Kota Iwahori, et al.
Molecular Therapy. Methods & Clinical Development
|
August 11, 2020
The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing
Janice M Riberdy, Sheng Zhou, Fei Zheng, et al.
Page
of 5